These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 33780423)

  • 21. Safety and preliminary efficacy of intranasal insulin for cognitive impairment in Parkinson disease and multiple system atrophy: A double-blinded placebo-controlled pilot study.
    Novak P; Pimentel Maldonado DA; Novak V
    PLoS One; 2019; 14(4):e0214364. PubMed ID: 31022213
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
    Athauda D; Maclagan K; Skene SS; Bajwa-Joseph M; Letchford D; Chowdhury K; Hibbert S; Budnik N; Zampedri L; Dickson J; Li Y; Aviles-Olmos I; Warner TT; Limousin P; Lees AJ; Greig NH; Tebbs S; Foltynie T
    Lancet; 2017 Oct; 390(10103):1664-1675. PubMed ID: 28781108
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A dose-finding and safety study of novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia in patients receiving multicycle chemotherapy.
    Glaspy J; Jadeja JS; Justice G; Kessler J; Richards D; Schwartzberg L; Rigas J; Kuter D; Harmon D; Prow D; Demetri G; Gordon D; Arseneau J; Saven A; Hynes H; Boccia R; O'Byrne J; Colowick AB
    Br J Cancer; 2001 Apr; 84 Suppl 1(Suppl 1):17-23. PubMed ID: 11308270
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combined rasagiline and antidepressant use in Parkinson disease in the ADAGIO study: effects on nonmotor symptoms and tolerability.
    Smith KM; Eyal E; Weintraub D;
    JAMA Neurol; 2015 Jan; 72(1):88-95. PubMed ID: 25420207
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment with nasal neuro-EPO improves the neurological, cognitive, and histological state in a gerbil model of focal ischemia.
    Rodríguez Cruz Y; Mengana Támos Y; Muñoz Cernuda A; Subirós Martines N; González-Quevedo A; Sosa Testé I; García Rodríguez JC
    ScientificWorldJournal; 2010 Nov; 10():2288-300. PubMed ID: 21103798
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Simvastatin as a neuroprotective treatment for Parkinson's disease (PD STAT): protocol for a double-blind, randomised, placebo-controlled futility study.
    Carroll CB; Webb D; Stevens KN; Vickery J; Eyre V; Ball S; Wyse R; Webber M; Foggo A; Zajicek J; Whone A; Creanor S
    BMJ Open; 2019 Oct; 9(10):e029740. PubMed ID: 31594876
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterizing a novel hyposialylated erythropoietin by intact glycoprotein and glycan analysis.
    García-Artalejo JA; Mancera-Arteu M; Sanz-Nebot V; Rodríguez T; Giménez E
    J Pharm Biomed Anal; 2022 May; 213():114686. PubMed ID: 35247653
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A double-blind, placebo-controlled and longitudinal study of riluzole in early Parkinson's disease.
    Jankovic J; Hunter C
    Parkinsonism Relat Disord; 2002 Mar; 8(4):271-6. PubMed ID: 12039422
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of the effect of one large dose of erythropoietin against cardiac and cerebral ischemic injury occurring during cardiac surgery with cardiopulmonary bypass: a randomized double-blind placebo-controlled pilot study.
    Joyeux-Faure M; Durand M; Bedague D; Protar D; Incagnoli P; Paris A; Ribuot C; Levy P; Chavanon O
    Fundam Clin Pharmacol; 2012 Dec; 26(6):761-70. PubMed ID: 21929528
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intranasal administration of recombinant human cartilage glycoprotein-39 as a treatment for rheumatoid arthritis: a phase II, multicentre, double-blind, randomised, placebo-controlled, parallel-group, dose-finding trial.
    Landewé RB; Houbiers JG; Van den Bosch F; in't Hout J; Verschueren PC; Meijerink JH; van den Hoogen FH; Masek BA; Bruyn GA; Wouters JM; Voskuyl AE; van Laar JM; Bijlsma JJ; van der Heijde DM; Breedveld FC; van de Putte LB; Miltenburg AM; de Keyser F
    Ann Rheum Dis; 2010 Sep; 69(9):1655-9. PubMed ID: 19778914
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Experimental evidence of the potential use of erythropoietin by intranasal administration as a neuroprotective agent in cerebral hypoxia.
    Merelli A; Caltana L; Lazarowski A; Brusco A
    Drug Metabol Drug Interact; 2011; 26(2):65-9. PubMed ID: 21756166
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recombinant human erythropoietin β: the effect of weekly dosing on anemia, quality of life, and long-term outcomes in pediatric cancer patients.
    Durmaz O; Demirkaya M; Sevinir B
    Pediatr Hematol Oncol; 2011 Sep; 28(6):461-8. PubMed ID: 21707225
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and efficacy of epigallocatechin gallate in multiple system atrophy (PROMESA): a randomised, double-blind, placebo-controlled trial.
    Levin J; Maaß S; Schuberth M; Giese A; Oertel WH; Poewe W; Trenkwalder C; Wenning GK; Mansmann U; Südmeyer M; Eggert K; Mollenhauer B; Lipp A; Löhle M; Classen J; Münchau A; Kassubek J; Gandor F; Berg D; Egert-Schwender S; Eberhardt C; Paul F; Bötzel K; Ertl-Wagner B; Huppertz HJ; Ricard I; Höglinger GU;
    Lancet Neurol; 2019 Aug; 18(8):724-735. PubMed ID: 31278067
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An Intranasal Formulation of Erythropoietin (Neuro-EPO) Prevents Memory Deficits and Amyloid Toxicity in the APPSwe Transgenic Mouse Model of Alzheimer's Disease.
    Rodríguez Cruz Y; Strehaiano M; Rodríguez Obaya T; García Rodríguez JC; Maurice T
    J Alzheimers Dis; 2017; 55(1):231-248. PubMed ID: 27662300
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Erythropoiesis-stimulating protein delivery in providing erythropoiesis and neuroprotection.
    Chang ZY; Chiang CH; Lu DW; Yeh MK
    Expert Opin Drug Deliv; 2008 Dec; 5(12):1313-21. PubMed ID: 19040394
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The neuroprotective and neurorescue effects of carbamylated erythropoietin Fc fusion protein (CEPO-Fc) in a rat model of Parkinson's disease.
    Thomas Tayra J; Kameda M; Yasuhara T; Agari T; Kadota T; Wang F; Kikuchi Y; Liang H; Shinko A; Wakamori T; Vcelar B; Weik R; Date I
    Brain Res; 2013 Mar; 1502():55-70. PubMed ID: 23380533
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase III trial of recombinant human erythropoietin therapy in nonanemic orthopedic patients subjected to aggressive removal of blood for autologous use: dose, response, toxicity, and efficacy.
    Goodnough LT; Price TH; Friedman KD; Johnston M; Ciavarella D; Khan N; Sacher R; Vogler WR; Wissel M; Abels RI
    Transfusion; 1994 Jan; 34(1):66-71. PubMed ID: 8273133
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of Erythropoietin in patients with acute myocardial infarction: five-year results of the REVIVAL-3 trial.
    Steppich B; Groha P; Ibrahim T; Schunkert H; Laugwitz KL; Hadamitzky M; Kastrati A; Ott I;
    BMC Cardiovasc Disord; 2017 Jan; 17(1):38. PubMed ID: 28109258
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia of chronic disease associated with cancer.
    Smith RE; Jaiyesimi IA; Meza LA; Tchekmedyian NS; Chan D; Griffith H; Brosman S; Bukowski R; Murdoch M; Rarick M; Saven A; Colowick AB; Fleishman A; Gayko U; Glaspy J
    Br J Cancer; 2001 Apr; 84 Suppl 1(Suppl 1):24-30. PubMed ID: 11308271
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Statistical analysis plan for the Erythropoietin in Traumatic Brain Injury trial: a randomised controlled trial of erythropoietin versus placebo in moderate and severe traumatic brain injury.
    Presneill J; Little L; Nichol A; French C; Cooper DJ; Haddad S; Duranteau J; Huet O; Skrifvars M; Arabi Y; Bellomo R; ;
    Trials; 2014 Dec; 15():501. PubMed ID: 25528574
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.